Skip to main content

Decode Stock to Return to Nasdaq Global Market

NEW YORK (GenomeWeb News) – Decode Genetics today said that its stock will be returned to the Nasdaq Global Market at the opening of trade on Monday, June 29.

The firm said that the reinstatement follows the Nasdaq Hearing and Listing Review Council's decision to reverse a February decision by the Listing Qualifications Panel to transfer Decode's stock to the Nasdaq Capital Market. Decode did not specify the reasons why its stock would be transferred back to the Global Market.

Just a few months ago, Decode's stock was in danger of being delisted from the Nasdaq Capital Market. The firm received a reprieve while the Nasdaq Listing and Hearing Review Council conducted a review and it continued to trade on that market.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.